PRA’s Vaccine Solutions group understands the unique challenges and characteristics of vaccine development. Right from the start, our experts will evaluate your clinical program needs and develop the most efficient study strategy.
Early Engagement Crucial to Develop Trial Design for Accelerated Schedule Vaccine Study
A case study describing PRA's involvement in an accelerated schedule vaccine study for poliomyelitis.
Recommendations on Writing a Clinical Study Report for a Study Conducted During the COVID-19 Pandemic
The clinical study report (CSR) is a crucial document in the drug development and regulatory submission process that describes the background,…
Succeeding with a Risk-Based Approach
A Phase III double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of Drug A in patients with moderate to severe…